Clinical Effects of Sacubitril/Valsartan Combined with Dapagliflozin in Patients with Diabetes and ST-segment Elevation Myocardial Infarction  

作　　者：Zhengbin Wang Zhifang Li Yiming Hou Panpan Wang Zhikang Zhao Shuo Wang Li Huang Lei Wang 

机构地区：[1]Department of Emergency,The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan Province 450052,China [2]Key Laboratory of Emergency and Trauma of Henan Province,Zhengzhou,Henan Province 450052,China

出　　处：《Cardiovascular Innovations and Applications》2023年第1期224-232,共9页心血管创新与应用(英文)

基　　金：This work was supported by the Key Scientific Research Project of Colleges and Universities in Henan Province(No.23A310030).

摘　　要：Objectives:This study was aimed at observing the clinical effects of sacubitril/valsartan combined with dapagliflozin on cardiac function and ventricular remodeling in patients with type 2 diabetes and ST-segment elevation myocardial infarction(STEMI).Methods:Between May 2019 and May 2022,we retrospectively analyzed 57 patients with diabetes and STEMI receiving percutaneous coronary intervention:32 patients receiving sacubitril/valsartan and dapagliflozin tablets com-prised the observation group and 25 patients receiving angiotensin converting enzyme inhibition(ACEI)or angiotensin receptor blockers (ARB)in combination with other hypoglycemic drugs comprised the control group.We compared the left ventricular end diastolic diameter(LVEDD),right ventricular end diastolic diameter(RVEDD),left ventricular ejection fraction(LVEF),N-terminal pro-B-type natriuretic peptide(NT-pro BNP),and noninvasive hemodynamic parameters at baseline and 3–6 months after treatment between the groups.Results:Before treatment,the parameters were similar between the observation group and control group.However,after 3-6 months of treatment,serum NT-pro BNP levels showed a greater decline in the observation group than the control group.Moreover,the LVEDD and LVEF improved more substantially in the observation group than the control group(P<0.05).RVEDD did not markedly change after treatment(P>0.05).After treatment,in the observation group,the cardiac index(CI)and cardiac output(CO)were significantly higher,and the thoracic fluid conduction(TFC)and systemic vascular resistance index(SVRI)were significantly lower,than those in the control group(P<0.05).Conclusions:Sacubitril/valsartan combination with dapagliflozin exerted better effects than ACEI or ARB with other hypoglycemic drugs in improving cardiac function and ventricular remodeling in patients with diabetes and STEMI.

关 键 词：sacubitril/valsartan DAPAGLIFLOZIN ventricular remodeling noninvasive hemodynamics 

分 类 号：R541.4[医药卫生—心血管疾病]